# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wolfe Research analyst Andy Chen initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Outperform rating.
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.
Goldman Sachs analyst Richard Law initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces ...
HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price t...
Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price tar...
Ladenburg Thalmann analyst Michael Higgins downgrades Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral.